What changed
What changedUnitedHealth Group reported adjusted net earnings of $4.69 per share for the third quarter 2026. Revenue was $112.7 billion, slightly below $113.2 billion in the comparable quarter 2025. The operating cost ratio fell to 12.8% from 13.5%, and the medical cost ratio fell to 88.4% from 89.9%. The debt‑to‑capital ratio rose to 41.7% as of September 30, 2026. The company repurchased $5.0 billion of its common stock and paid $6.2 billion in dividends year to date.

Company history
October 2026
UNITEDHEALTH GROUP INC: 12 recorded developments from 3 official sources in 2026-10.
- 2026-10-13: The year-over-year decrease in medical care ratio was driven by medical cost management initiatives, benefit design changes and pricing discipline, as well as care delivery enhancements focused on affordability and integrated value-based care. Source
- 2026-10-13: The third quarter 2026 operating cost ratio was 12.8% compared to 13.5% in the third quarter 2025, reflecting realized operating efficiencies partially offset by accelerating investments in technology, processes and people to improve care delivery and consumer and clinician experiences. Source
- 2026-10-13: Optum Health’s third quarter 2026 revenues of $22.9 billion decreased 10% year-over-year as a result of fewer value-based care patients served in markets where Optum lacked sufficient value-based care presence to sustain its clinicians. Source
- 2026-10-13: UnitedHealth Group’s medical cost ratio was 88.4% for the third quarter 2026, reflecting both medical cost management and pricing discipline, as well as benefit design changes and care delivery enhancements focused on affordability and integrated value-based care. Source
- 2026-10-13: Affordability, Rural Care and Benefits The company is removing prior approval requirements, standardizing approval processes across the industry, reducing paperwork requirements and increasing transparency into the approval process, making it quicker and simpler for clinicians to treat p Source
- 2026-10-13: Approval Reform To combat high prescription drug costs, the company is lowering out-of-pocket costs for patients and bringing greater transparency to pharmacy benefits, setting a new standard for the industry. Source
- 2026-10-13: Expanding eligibility for UnitedHealthcare’s Gold Card status – exempting high-performing clinicians from routine approval requirements entirely – and removing requirements for home health services, eliminating nearly 10% of total UnitedHealthcare prior approval volume. Source
- 2026-10-13: Released an independent review of the HouseCalls program that showed the sampled diagnoses were overwhelmingly supported by medical records, with an error rate nearly three times lower than the rate reported by recent Federal CMS audits. Source
- 2026-10-13: The third quarter 2026 operating cost ratio was 12.8% compared to 13.5% in the third quarter 2025, reflecting realized operating efficiencies partially offset by accelerating investments in technology, processes and people to improve care delivery and consumer and clinician experiences. Source
- 2026-10-13: Launched the industry’s first fully transparent, fee-based pharmacy care model to bring greater clarity, predictability and affordability by decoupling PBM pricing from drug list prices and prescription volume, aligning incentives with patients and plan sponsors and introducing digital t Source
- 2026-10-13: Optum Health’s third quarter 2026 revenues of $22.9 billion decreased 10% year-over-year as a result of fewer value-based care patients served in markets where Optum lacked sufficient value-based care presence to sustain its clinicians. Source
- 2026-10-13: UnitedHealth Group Incorporated issued a press release announcing its third quarter 2026 results on October 13, 2026. Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
Updated Full Year 2026 Earnings Outlook to At Least $19.50 Per Share; Adjusted Earnings of At Least $20.50 Per Share
Said October 13, 2026 · Period named: Full Year 2026 · Source · Our article
Not yet checked against later reports.
Announced nationwide coverage expansion for doula care with employer-sponsored plans, with more than 7 million members eligible for coverage by January 2027.
Said October 13, 2026 · Period named: January 2027 · Source · Our article
Not yet checked against later reports.
Continued actions the company has taken to address these challenges include the below, with further commitments expected in 2027.
Said October 13, 2026 · Period named: 2027 · Source · Our article
Not yet checked against later reports.
Committed to voluntarily eliminating and rebating profits from individual Affordable Care Act coverage offerings in 2026, returning this money directly to approximately 1 million ACA members as Congress works toward longer-term solutions to strengthen the stability and affordability of these plans.
Said October 13, 2026 · Period named: 2026 · Source · Our article
Not yet checked against later reports.
The company now expects full year 2026 adjusted net earnings of at least $20.50 per share, incorporating experience through the third quarter 2026.
Said October 13, 2026 · Period named: full year 2026 · Source · Our article
Not yet checked against later reports.
The company continues to target a long-term debt-to-capital ratio of approximately 40.0% by year-end.
Said October 13, 2026 · Source · Our article
Not yet checked against later reports.
Show all (7)
Committed to 100% pass-through of manufacturer drug rebate discounts to clients by January 1, 2028.
Said October 13, 2026 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| November 9, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 77,211,952 | $28,342,963,233 | +0.5% | Q3 2026 |
| State Street | 45,703,591 | $16,776,874,184 | +0.2% | Q3 2026 |
| Fidelity (FMR) | 31,060,207 | $11,401,580,315 | +11.0% | Q3 2026 |
| Geode Capital Management | 20,745,390 | $7,580,119,656 | -4.6% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 12,736,973 | $5,293,868,088 | — | Q2 2026 |
| Wellington Management | 10,865,278 | $3,988,426,249 | +1.8% | Q3 2026 |
| Capital Research Global Investors | 8,634,268 | $3,170,024,243 | -18.0% | Q3 2026 |
| Renaissance Technologies | 2,226,720 | $817,384,838 | +506.7% | Q3 2026 |
| Citadel Advisors | 2,035,293 | $747,115,354 | +91.3% | Q3 2026 |
| Millennium Management | 1,241,266 | $455,643,923 | -23.3% | Q3 2026 |
| D. E. Shaw & Co. | 428,766 | $157,391,423 | -13.2% | Q3 2026 |
| Two Sigma Investments | 379,884 | $139,447,819 | +93.1% | Q3 2026 |
| Tiger Global Management | 297,452 | $109,188,679 | 0.0% | Q3 2026 |
| Appaloosa (David Tepper) | 90,000 | $24,353,100 | — | Q1 2026 |
| Bridgewater Associates | 51,713 | $18,982,808 | +734.5% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.